Downregulation of BRAF‑activated non‑coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells

Li,Jing; Wang,Jinfeng; Zhou,Wei; Zhang,Shuqin; Le,Yuan; He,Rong

doi:10.3892/ol.2017.6770

Downregulation of BRAF‑activated non‑coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells

Authors:
- Jing Li
- Jinfeng Wang
- Wei Zhou
- Shuqin Zhang
- Yuan Le
- Rong He
View Affiliations

Affiliations: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Pediatrics, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Clinical Genetics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: August 18, 2017 https://doi.org/10.3892/ol.2017.6770
Pages: 4751-4757
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long non‑coding RNA BRAF‑activated non‑coding RNA (BANCR) has been reported to serve essential roles in the progress of a various cancer types. The purpose of the present study was to investigate the effect of lncRNA BANCR in HCC cells. The expression of BANCR in the HCC cell line Huh7 and a normal liver cell line were determined using reverse transcription‑quantitative polymerase chain reaction. The expression of BANCR in Huh7 cells was downregulated by short hairpin (sh)RNA. Subsequently, the proliferation, apoptosis, migration and invasion rates were determined, along with the activity of MAPK/ERK kinase (MEK) and mitogen‑activated protein kinase signaling pathways. The results revealed that BANCR was overexpressed in Huh7 cells when compared with normal liver cells. The downregulation of BANCR significantly inhibited the proliferation and colony formation ability, and induced cell cycle arrest and apoptosis of Huh7 cells. The migration and invasion of Huh7 cells were also suppressed in BANCR shRNA‑transfected cells. The downregulation of BANCR significantly inhibited the activity of MEK, extracellular signal‑regulated kinase and janus kinase signaling pathways. Collectively, these findings demonstrated that the lncRNA BANCR is oncogenic in Huh7 cells, and may be a promising molecular target for HCC therapy.

View Figures

View References

1	Knudsen ES, Gopal P and Singal AG: The changing landscape of hepatocellular carcinoma: Etiology, genetics and therapy. Am J Pathol. 184:574–583. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ahn J and Flamm SL: Hepatocellular carcinoma. Dis Mon. 50:556–573. 2004. View Article : Google Scholar : PubMed/NCBI
3	Everson GT: Increasing incidence and pretransplantation screening of hepatocellular carcinoma. Liver Transpl. 6 (6 Suppl 2):S2–S10. 2000. View Article : Google Scholar : PubMed/NCBI
4	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bruix J and Llovet JM: Major achievements in hepatocellular carcinoma. Lancet. 373:614–616. 2009. View Article : Google Scholar : PubMed/NCBI
6	Olsen SK, Brown RS and Siegel AB: Hepatocellular carcinoma: Review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 3:55–66. 2010. View Article : Google Scholar : PubMed/NCBI
7	Forner A and Bruix J: Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 13:750–751. 2012. View Article : Google Scholar : PubMed/NCBI
8	Meseure D, Alsibai Drak K, Nicolas A, Bieche I and Morillon A: Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. Biomed Res Int. 2015:3202142015. View Article : Google Scholar : PubMed/NCBI
9	Tsai MC, Spitale RC and Chang HY: Long intergenic noncoding RNAs: New links in cancer progression. Cancer Res. 71:3–7. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361. 2011. View Article : Google Scholar : PubMed/NCBI
11	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
12	Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M and Khavari PA: BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 22:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI
13	McCarthy N: Epigenetics. Going places with BANCR. Nat Rev Cancer. 12:4512012. View Article : Google Scholar : PubMed/NCBI
14	Zhang ZX, Liu ZQ, Jiang B, Lu XY, Ning XF, Yuan CT and Wang AL: BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferation via regulation of NF-κB1. Biochem Biophys Res Commun. 465:225–231. 2015. View Article : Google Scholar : PubMed/NCBI
15	Zheng H, Wang M, Jiang L, Chu H, Hu J, Ning J, Li B, Wang D and Xu J: BRAF-activated long non-coding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor. Cancer Res Treat. 48:698–707. 2016. View Article : Google Scholar : PubMed/NCBI
16	Shi Y, Liu Y, Wang J, Jie D, Yun T, Li W, Yan L, Wang K and Feng J: Downregulated long noncoding RNA BANCR promotes the proliferation of colorectal cancer cells via downregulation of p21 expression. PLoS One. 10:e01226792015. View Article : Google Scholar : PubMed/NCBI
17	Su S, Gao J, Wang T, Wang J, Li H and Wang Z: Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma. Tumour Biol. 36:7205–7211. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J and Sun Y: BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 8:1947–1952. 2014.PubMed/NCBI
19	Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, et al: Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer. 13:682014. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L and Sha N: Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One. 9:e1008932014. View Article : Google Scholar : PubMed/NCBI
22	Li L, Zhang L, Zhang Y and Zhou F: Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. Biomed Pharmacother. 72:109–112. 2015. View Article : Google Scholar : PubMed/NCBI
23	Su S, Gao J, Wang T, Wang J, Li H and Wang Z: Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma. Tumour Biol. 36:7205–7211. 2015. View Article : Google Scholar : PubMed/NCBI
24	Jiang W, Zhang D, Xu B, Wu Z, Liu S, Zhang L, Tian Y, Han X and Tian D: Long non-coding RNA BANCR promotes proliferation and migration of lung carcinoma via MAPK pathways. Biomed Pharmacother. 69:90–95. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zheng JH, Follis Viacava A, Kriwacki RW and Moldoveanu T: Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar : PubMed/NCBI
26	Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E and Boise LH: Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
27	Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D and Sun Y: BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 8:869–875. 2014.PubMed/NCBI
28	Galuppo R, Ramaiah D, Ponte OM and Gedaly R: Molecular therapies in hepatocellular carcinoma: What can we target? Dig Dis Sci. 59:1688–1697. 2014. View Article : Google Scholar : PubMed/NCBI
29	Zhou Q, Lui VW and Yeo W: Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 7:1149–1167. 2011. View Article : Google Scholar : PubMed/NCBI
30	Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
31	Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS and Diehl AM: Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis. 27:748–757. 2006. View Article : Google Scholar : PubMed/NCBI
32	Delire B and Stärkel P: The Ras/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications. Eur J Clin Invest. 45:609–623. 2015. View Article : Google Scholar : PubMed/NCBI
33	Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar : PubMed/NCBI
34	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
35	Gao JJ, Shi ZY, Xia JF, Inagaki Y and Tang W: Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol. 21:12059–12070. 2015. View Article : Google Scholar : PubMed/NCBI
36	Chen C and Wang G: Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015. View Article : Google Scholar : PubMed/NCBI